
Datexim is an AI-powered company focused on revolutionizing cervical cancer diagnostics. Their primary solution, CytoProcessor®, is the first CE-marked AI-based image analysis solution for cervical cancer screening. By leveraging artificial intelligence and digital pathology, Datexim aims to significantly increase diagnostic accuracy, reduce the risk of missed cases, and save women's lives. The company was founded with a passion for image processing, analysis, and artificial intelligence, inspired by research projects assisting pathologists in cancer diagnosis. They strive to make their solutions accessible to low-resource countries and improve diagnostic and preventive care worldwide.

Datexim is an AI-powered company focused on revolutionizing cervical cancer diagnostics. Their primary solution, CytoProcessor®, is the first CE-marked AI-based image analysis solution for cervical cancer screening. By leveraging artificial intelligence and digital pathology, Datexim aims to significantly increase diagnostic accuracy, reduce the risk of missed cases, and save women's lives. The company was founded with a passion for image processing, analysis, and artificial intelligence, inspired by research projects assisting pathologists in cancer diagnosis. They strive to make their solutions accessible to low-resource countries and improve diagnostic and preventive care worldwide.
Core product: CytoProcessor — CE-marked AI platform for cervical cancer screening
Headquarters: Caen, France
Founded: 2011
Clinical performance: Reported diagnostic sensitivity ~96%
Employees: 16
Cervical cancer screening and diagnostic workflow automation in anatomical pathology laboratories.
2011
Biotechnology
“ODYSSEE VENTURE, Normandie Participations, Normandie Incubation, MEDS Healthcare IT”